Lyell reported a third quarter 2026 net loss of $45.5 million as it increased investments in its pivotal chimeric antigen receptor (CAR) T-cell therapy trials. The company reported strong efficacy data for its lead candidate, ronde-cel, and secured an $80.0 million private placement to extend its cash runway into 2028.
Key Highlights
- Clinical data for ronde-cel in the 3L+ PiNACLE trial showed a 77% complete response rate and a 91% overall response rate among 44 efficacy-evaluable patients.
- Management reaffirmed the timeline for pivotal data disclosure in mid-2027, with a Biologics License Application submission expected in the second half of 2027.
- Cash, cash equivalents, and marketable securities totaled $194.0 million at quarter-end, which, combined with recent financing, supports operations beyond anticipated regulatory milestones.